The Honourable Marjorie Michel, Federal Minister of Health, today tabled the 2025 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Commons.
The 2025 Annual Report reviews trends in the prices and sales of patented medicines in Canada. Sales of patented medicines in 2025 were $24.4 billion and accounted for 48% of the sales of all medicines in Canada.
The report also sets out findings on spending on pharmaceutical research and development in Canada, as well as updated information on the PMPRB's price review and reporting activities in 2025.
The PMPRB reviews patented medicine prices to protect Canadians from any patent abuse related to excessive prices. The PMPRB also reports on Canadian pharmaceutical trends, contributing to a greater understanding of the changing landscape.